Financial Performance - The company's revenue for Q3 2025 was CNY 434,517,125.34, representing a 2.45% increase year-over-year, while the year-to-date revenue was CNY 1,317,076,113.48, showing a slight decrease of 0.39% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2025 was CNY 4,710,268.28, a significant increase of 1,316.05% year-over-year, while the year-to-date net profit was CNY -1,100,159.67, reflecting a decrease of 103.04%[5]. - Basic and diluted earnings per share for Q3 2025 were both CNY 0.0119, marking a substantial increase of 1,222.22% compared to the same period last year[5]. - Total operating revenue for the current period is ¥1,317,076,113.48, a slight decrease of 0.01% from ¥1,322,234,413.75 in the previous period[20]. - Total operating costs increased to ¥1,292,835,287.81, up 2.1% from ¥1,265,739,711.39 in the previous period[20]. - Net profit for the current period is -¥1,943,993.04, a decline from a net profit of ¥36,142,245.31 in the previous period[21]. - The total profit for the current period is ¥5,196,279.40, a decrease of 88.5% from ¥45,366,860.75 in the previous period[21]. - Basic and diluted earnings per share for the current period are both -¥0.0028, down from ¥0.0906 in the previous period[21]. Assets and Liabilities - Total assets as of September 30, 2025, were CNY 5,901,757,106.67, an increase of 1.32% from the end of the previous year[5]. - Total current assets as of September 30, 2025, amounted to ¥3,138,678,439.75, an increase from ¥3,046,358,976.71 at the beginning of the period, reflecting a growth of approximately 3.8%[16]. - Total liabilities increased from ¥1,463,777,022.00 to ¥1,565,890,623.97, marking an increase of approximately 7%[17]. - Short-term borrowings rose sharply from ¥59,317,883.35 to ¥163,096,350.00, indicating an increase of about 174.5%[17]. - Total non-current assets decreased slightly from ¥2,778,564,582.50 to ¥2,763,078,666.92, a decline of approximately 0.6%[17]. - The company's equity attributable to shareholders decreased from ¥4,360,679,835.59 to ¥4,335,419,133.28, a decline of approximately 0.6%[17]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 28,012[10]. - The largest shareholder, Yan Xiaohui, holds 22.15% of shares, totaling 88,585,200 shares[10]. - The second-largest shareholder, Yin Guoping, holds 16.04% of shares, totaling 64,155,000 shares[10]. - The company has repurchased a total of 3,200,000 shares, accounting for 0.80% of the total share capital[10]. - There are no changes in the top 10 shareholders or the top 10 unrestricted shareholders due to securities lending[11]. Research and Development - Research and development expenses for the first nine months of 2025 amounted to CNY 55,846,719.90, a 34.05% increase compared to CNY 41,660,613.38 in the same period of 2024[8]. - Research and development expenses rose significantly to ¥55,846,719.90, an increase of 34.1% compared to ¥41,660,613.38 in the previous period[20]. Cash Flow - The net cash flow from operating activities is -¥185,389,921.10, worsening from -¥9,039,204.85 in the previous period[22]. - Cash flow from investment activities shows a net outflow of -¥641,811,573.14, compared to a net inflow of ¥654,043,833.73 in the previous period[22]. - Cash and cash equivalents at the end of the period decreased to ¥91,670,398.89 from ¥831,355,002.16 at the end of the previous period[23]. - Cash and cash equivalents decreased significantly from ¥745,590,069.83 to ¥196,887,334.20, representing a decline of about 73.6%[16]. Other Financial Metrics - The company experienced a 30.08% increase in trading financial assets, reaching CNY 1,171,149,515.19, attributed to enhanced cash management[8]. - The company recorded a 665.10% increase in asset disposal gains, amounting to CNY 723,042.49, compared to CNY 94,503.36 in the previous year[9]. - The company’s weighted average return on net assets was 0.11%, a decrease of 0.03% compared to the previous year[5]. - The company reported a 1260.37% increase in financial expenses, totaling CNY 6,348,455.34, primarily due to increased interest expenses and reduced exchange gains[8]. Inventory and Receivables - The total inventory increased from ¥270,528,377.11 to ¥287,509,343.47, representing a growth of about 6.3%[16]. - The company's accounts receivable rose from ¥236,424,308.04 to ¥300,912,990.89, an increase of approximately 27.3%[16]. - The total amount of other current assets increased from ¥452,087,706.59 to ¥694,366,795.45, reflecting a growth of about 53.7%[16].
宏源药业(301246) - 2025 Q3 - 季度财报